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Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows promise in recent
trials. Synthetic-biology-based engineering of T lymphocytes to express high-affinity antigen receptors
can overcome immune tolerance, which has been amajor limitation of immunotherapy-based strategies. Ad-
vances in cell engineering and culture approaches to enable efficient gene transfer and ex vivo cell expansion
have facilitated broader evaluation of this technology, moving adoptive transfer from a ‘‘boutique’’ applica-
tion to the cusp of a mainstream technology. The major challenge currently facing the field is to increase the
specificity of engineered T cells for tumors, because targeting shared antigens has the potential to lead to on-
target off-tumor toxicities, as observed in recent trials. As the field of adoptive transfer technology matures,
the major engineering challenge is the development of automated cell culture systems, so that the approach
can extend beyond specialized academic centers and become widely available.Introduction
Adoptive T cell transfer involves the isolation and reinfusion of T
lymphocytes into patients to treat disease. The ultimate objec-
tive of the process is conceptually the same as that of a success-
ful T cell immunization, namely the stimulation and expansion of
potent and antigen-specific T cell immunity. Adoptive T cell
transfer additionally offers the potential to overcome one of the
significant limitations associated with vaccine-based strategies,
specifically the requirement to de novo activate and expand a tu-
mor antigen-specific T cell response in patients who are often
immune compromised and deeply tolerant to cancer antigens
or to antigens that are expressed during chronic infection.
Targeting of disease through the adoptive transfer of lympho-
cytes was first reportedmore than 50 years ago in rodent models
(Mitchison, 1955). Improved understanding of T cell biology,
including the mechanisms for T cells activation and recognition
of targets, the role of accessory surface molecules and signal
transduction pathways involved in the regulation of T cell func-
tion and survival, as well as the identification and cloning of sol-
uble T cell growth factors, has facilitated the ability to expand
ex vivo large numbers of T cells for adoptive immunotherapy.
There are several excellent reviews of the rationale and experi-
mental basis for adoptive T cell therapy of tumors (Cheever
and Chen, 1997; Greenberg, 1991; Restifo et al., 2012).
Significant effort has been extended over the past few years to
evaluate the potential for adoptive T cell transfer to treat cancer.
A number of strategies have been evaluated, initially using T cells
isolated from tumor-infiltrating lymphocytes (TILs) (Dudley et al.,
2008). Adoptive transfer of bulk T lymphocytes, obtained from
the periphery and expanded ex vivo to generate large numbers
prior to reinfusion into patients, is an alternative strategy for
adoptive T cell therapy (Rapoport et al., 2005). Initial approaches
to apply this strategy involved leukapheresis of peripheral blood
mononuclear cells (PBMCs) from patients followed by bulk
ex vivo expansion and reinfusion along with exogenous inter-
leukin-2 (IL-2). This approach does not specifically enrich for an-tigen-specific T cells, but rather generates a population of acti-
vated T cells with lowered triggering thresholds. Clinical trials
to evaluate the potential of adoptively transferred autologous
activated T cells to augment stem cell transplants for hematolog-
icmalignancies showed that infusion of autologous costimulated
T cells resulted in a rapid reconstitution of lymphocyte numbers
(Laport et al., 2003) and randomized trials demonstrated that
expanded cells were functional (Rapoport et al., 2005). Data
frommore recent clinical trials using engineered antigen-specific
T cells have started to reveal the full potential of adoptive T cell
therapy to effectively target cancer, with objective clinical activ-
ity in a number of cases (Brentjens et al., 2013; Johnson et al.,
2009; Kochenderfer et al., 2012) including complete and long-
lasting durable clinical responses observed in patients with
late-stage, chemotherapy-resistant leukemias (Grupp et al.,
2013; Kalos et al., 2011). These recent results have shown that
it is possible to achieve a long-standing objective of adoptive
T cell therapy. This objective has been to recapitulate the end
result of a successful T cell vaccine, with robust T cell expansion
in vivo, potent antitumor activity, T cell contraction, and long-
term functional persistence of a memory T cell subset. However,
we propose that the goal with engineered T cells is not simply to
recapitulate T cell vaccines, but rather to use the emerging disci-
pline of synthetic biology, which combines elements of engineer-
ing and molecular biology to create new immune systems with
enhanced functionalities (Chen et al., 2012). In this regard, the
principles of gene transfer combined with adoptive cellular ther-
apy are poised to overcome the fundamental limitations associ-
ated with central and peripheral tolerance and enable the potent
and efficient ‘‘at-will’’ targeting of tumors. In this article we sum-
marize the state of the art and highlight outstanding issues for the
effective application of engineered T cell therapy to treat cancer.
Using Bispecific T Cells to Overcome Tolerance
The great majority of to-date targeted tumor antigens are self-
antigens, normally expressed during development andImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 49
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Figure 1. Engineered T Cells that Have
Retargeted Specificity
Bispecific and trispecific T cells are created by
introduction of genes that encode TCRs and CARs
of desired specificity and affinities for tumors. The
T cells retain expression of the endogenous TCR,
unless this is knocked down by various ap-
proaches. CARs target surface antigens in an
MHC-independent fashion. Abbreviations are as
follows: Costim, cosignaling domain such as CD28
or 4-1BB; LAT, linker for activation of T cells; scFv,
single-chain variable fragment; ZAP70, zeta chain
associated protein kinase 70 kDa.
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between T cell receptors specific for self-antigens expressed by
tumors and T cell receptors specific for virus antigens has been
summarized recently; these comparative analyses have revealed
that TCR from T cells that recognize self-tumor antigens have
substantially lower affinities (approximately 1.5 logs) for cognate
MHC:peptide complexes compared to their virus-specific
counterparts (Aleksic et al., 2012; Cole et al., 2007). This obser-
vation, which reflects the impact of central tolerance on the T cell
repertoire to self-antigens, points to the fact that T cells that
escape central tolerance and have the potential to respond to
the self-target antigens will manifest in most cases suboptimal
activation in terms of antitumor activity. The high tolerance to tu-
mor antigens with normal and/or developmental expression
combined with the potent immunosuppressive microenviron-
ment often present at the tumor site support the premise that
enhancing antitumor immunity by the adoptive transfer of
‘‘native’’ T cells may not be sufficient to induce tumor cell death
in most patients with advanced malignancy.
Gene-transfer-based strategies have been developed to over-
come the consequences of immune tolerance on the tumor-spe-
cific T cell repertoire. These approaches provide the potential to
redirect T cells to effectively target tumors by the transfer of an-
tigen-specific T cell receptor a and b chains (abTCR) or chimeric
antigen receptors (CARs) composed of antibody binding do-
mains fused to T cell signaling domains. In each case recipient
T cells acquire the engineered, tumor-specific specificity while
retaining their initial specificity (Figure 1).
The primary source for isolating tumor-specific abTCR has
been tumor-specific T cell clones obtained from cancer patients
or healthy volunteers. A number of approaches have been devel-
oped to isolate such T cells based on in vitro stimulation strate-
gies by peptides or whole antigen. These approaches have in
general been tedious and inefficient, at least in part because of
the lack of robust in vitro expansion protocols and the low fre-
quency of such T cells in peripheral blood. Additionally, because
of the impact of central tolerance on the T cell repertoire, T cells
isolated by these approaches have typically been of low affinity
with at best modest antitumor activity.50 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.Rational high-throughput genetic
mutagenesis approaches have been
applied to enhance the affinity of tumor-
antigen-specific abTCR (Chervin et al.,
2008; Li et al., 2005), and such efforts
have resulted in the ability to molecularly
engineer abTCR with substantially higheraffinities for target antigens (Li et al., 2005). Alternative strategies
to improve abTCR avidity by engineering TCR chains have also
been pursued (Kuball et al., 2009).
Affinity-enhanced abTCR-based engineering approaches
have certain inherent biological advantages, most notably that
essentially all cellular proteins can be targeted because the
approach is not limited to the targeting of cell surface epitopes
and the primary T cell activation signal is delivered in a physio-
logical context, which may be relevant for optimal functionality
of the infused T cells. On the other hand, this approach suffers
from certain disadvantages; in particular, abTCR-based target-
ing approaches remain susceptible to the common tumor
escape mechanisms of MHC downmodulation and altered pep-
tide processing; furthermore, the mutagenesis process has the
potential to result in the generation of neo-epitopes that can
become the target of humoral and cellular immune responses
in patients.
An additional concern for the broader implementation of affin-
ity-enhanced abTCR relates to the development of secondary
and potentially deleterious specificities as a consequence of
the mutagenesis and enhanced affinity process (Zhao et al.,
2007). As discussed in more detail below, establishing robust
and systematic strategies to evaluate this potential on a case-
by-case basis will be critical for broader implementation of this
approach.
Engineering of T cells by the introduction of chimeric antigen
receptors (CARs) is an alternative approach to redirect T cell
specificity (Gross et al., 1989). CARs are synthetic polypeptides
that contain three distinct modules: an extracellular target bind-
ingmodule, a transmembranemodule that anchors themolecule
into the cell membrane, and an intracellular signalingmodule that
transmits activation signals. The target binding module is usually
generated by scFv determinants isolated from antibodies, linked
in a single chain through linker polypeptide sequences. Trans-
membranemodules aremost commonly derived frommolecules
involved in T cell function such as CD8 and CD28. The intracel-
lular module almost always consists of the zeta chain of the
TCR complex responsible for transmitting TCR engagement-
mediated activation signals to cells. As discussed in more detail
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domains associated with T cell functions in efforts to augment
zeta signaling in a physiologically relevant manner.
CAR-based strategies provide distinct advantages in terms of
redirecting effective antitumor activity: because the target-bind-
ing moiety is derived from antibodies with affinities several or-
ders of magnitude higher than abTCR, CAR-engineered cells
bypass the fundamental issue of central tolerance. Because
CARs recognize intact cell surface proteins, targeting of target
cells is neither MHC restricted nor dependent on processing
and effective presentation of target epitopes, and consequently
CAR-based approaches are insensitive to tumor escape mech-
anisms related to HLA downmodulation and altered processing
escape mechanisms, an issue that is distressingly common
in human carcinoma (Vitale et al., 2005). On the other hand, a
limitation of the CAR-based approach is that they are restricted
to targeting of cell surface determinants. A recent report has
described the development of CARs that bind to the intracellular
antigen WT-1 via antibody scFv domains that bind to MHC class
I:peptide complexes (Dao et al., 2013). Finally, because CARs
are chimeric molecules that include unique junctional fragments
and murine sequences in the scFv domains, CAR-modified
T cells can be targeted by patient humoral and cellular immune
responses.
Approaches to Genetically Engineer Lymphocytes
Advances in basic molecular biology have precipitated a number
of approaches to engineer lymphocytes at the genomic, RNA,
epigenetic, and protein levels, with the goal of pharmacologically
enhancing the immune system. Approaches to engineer lympho-
cytes have been reviewed previously (June et al., 2009). The
combination of diverse approaches to effectively engineer
T cells combined with recently acquired mechanistic insights
into T cell biology and tumor immunity have converged to the
point where the rational engineering of potent antitumor T cell im-
munity is a practical and clinically testable reality. The majority of
clinical approaches have employed T cells engineered to stably
express transgenes via virus-based transduction. Virus-medi-
ated gene transfer approaches typically employ vectors that
are derived from gamma retroviruses or more recently lentivi-
ruses, principally because of their ability to integrate into the
host genome and drive long-term transgene expression, as
well as for their low intrinsic immunogenicity. Gammaretrovi-
rus-based transduction requires replicating cells for viral integra-
tion into genomic DNA, whereas lentiviral vectors can also
integrate into nondividing cells; lentiviral vectors also appear to
be less susceptible to silencing by host restriction factors and
can deliver larger DNA sequences than can retroviruses (Naldini
et al., 1996). Although virus-based approaches result in reason-
ably efficient transduction of primary T cells, they have consider-
able limitations in terms of cost to manufacture clinical-grade
material, the total size of DNA that can be included in the virus
vectors, and the potential, principally for retroviruses, for the
integration events to result in insertional oncogenesis. A new vi-
rus-based system that has not yet entered clinical trials is based
on foamy virus vectors, which possess favorable integration
properties and are not pathogenic in humans (Williams, 2008).
Non-virus-based approaches benefit from lower manufacturing
cost and are in principle less immunogenic than viral ap-proaches. Although such approaches are theoretically safer
because they are not dependent on viral elements integrating
into host DNA, their safety record is shorter than that of virus-
based vectors. Nonviral approaches to introduce transgenes
into T cells involve the utilization of transposon elements such
as sleeping beauty and piggybac as well as zinc-finger nuclease,
TALEN, and CRISPR/Cas9 based-technologies, which allow for
the ability to engineer T cell populations with transgene inser-
tions into specific chromosomal loci or that are biallelically dis-
rupted for specific genes (Hackett et al., 2010; Perez et al.,
2008; Reyon et al., 2012). Such technologies offer significant po-
tential to be able to engineer T cells in a manner that allows for
the ability to interrupt or otherwise modulate expression of
particular proteins that may be deleterious to therapeutic func-
tion.
As discussed above, a potential safety concern related to the
infusion of engineered T cells is integration-related insertional
mutagenesis and cellular transformation, which has been
demonstrated with the genetic engineering of hematopoietic
stem cells (Hacein-Bey-Abina et al., 2008). Retrovirally modified
T cells have been shown to persist for more than a decade
without adverse effects after adoptive transfer in patients with
congenital and acquired immunodeficiency (Muul et al., 2003;
Scholler et al., 2012), indicating that the retrovirus-based ap-
proaches to genetically modify mature human T cells are funda-
mentally safe. There are less data available on use of lentiviruses,
but to date no safety concerns have been raised, and analysis of
transduced T cells recovered from patients indicates that the
lentiviral integration sites are not random and do not favor
proto-oncogenes or tumor suppressor genes (Bushman, 2007;
Wang et al., 2009).
For some applications, permanent genomic alteration may not
be necessary for therapeutic efficacy, or transient expression
may be required to mitigate potential unanticipated toxicity. In
situations where transient gene transfer is required, nonintegrat-
ing viruses, such as the adenovirus-based Ad5-35 vectors, can
achieve high efficiencies of gene transfer to human T cells (Perez
et al., 2008). One emerging alternative to virus-mediated gene
transfer approaches is RNA transfection. Primary human T lym-
phocytes transiently express proteins for at least a week after
electroporation via in vitro-transcribed mRNA, and such engi-
neered cells mediate potent and antigen-specific effector func-
tions (Zhao et al., 2010). RNA electroporation has been used to
deliver message for TCRs or CARs, chemokine receptors or cy-
tokines (Mitchell et al., 2008; Rowley et al., 2009; Yoon et al.,
2009). Because RNA electroporation is a cost-effective and effi-
cient mechanism to engineer T cells, this approach is attractive
for high-throughput and iterative testing of novel constructs
and/or targets, and clinical trials using mRNA-electroporated
lymphocytes are ongoing at several centers. The transient nature
of RNA-based strategies provides considerable safety advan-
tages, particularly when exploring the potential to target antigens
not previously evaluated byCAR technology andwhere low-level
expression in normal tissues may be problematic in terms of
toxicity. Finally, the flexibility of this platform allows for the ability
to cotransfer multiple transcripts and augment T cell function by
introducing molecules that enhance costimulation and effector
functions, mediate homing to target tissues, or cotarget multiple
antigens.Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 51
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Figure 2. Cell Culture Approaches
CTLs express abTCRs and are stimulated by APCs that express MHC class I.
Feeder cells or artificial APC (aAPC) that express the costimulatory ligands 4-
1BBL and CD83 or beads coated with agonistic antibodies enhance growth
and function. T cells can be stimulated by beads or cell-based aAPC in the
presence of various cytokines.
Immunity
ReviewAn additional challenge for the field is the ability to more pre-
cisely control the activity of transferred engineered cells. Initial
efforts focused on developing approaches to ablate engineered
cells through the introduction of ‘‘suicide genes’’ such as herpes
simplex virus thymidine kinase (TK); these initial efforts demon-
strated the potential for immune-based rejection as a result of
targeting TK-derived sequences (Marktel et al., 2003). More
recently, an inducible system based on a fusion protein
comprised of an extracellular FK506 binding domain linked to
human caspase-9 signaling domains to deliver apoptotic signals
in response a small molecule-mediated dimerization has been
developed and is currently being evaluated in clinical trials (Di
Stasi et al., 2011). Another potential approach is to engineer
T cells to express signaling pathways that causes the T cell to
destroy itself after a defined number of cell divisions (Friedland
et al., 2009). Looking forward, the development of approaches
that enable modulation of T cell function and activity rather
than T cell ablation are likely to result in more precisely tuned
T cell specificity and function.
Although the ability to redirect T cell specificity to target anti-
gens of choice has perhaps been themost obvious development
in the field of T cell-based gene therapy, there are other aspects
of T cell biology that are amenable to genetic manipulation and
probably are important to address for the successful broad52 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.application of adoptive immunotherapy. These aspects include
long-term functional persistence, trafficking of effector cells
and accumulation at the tumor site, and engagement of costimu-
latory receptors to mediate a robust effector response. In addi-
tion, infused T cells must be able to resist mechanisms of
exhaustion, senescence, and immunosuppression by the tumor
microenvironment, to avoid the host humoral and cellular im-
mune responses, and additionally to be amenable to deletion
on demand to mitigate potential toxicity issues. Some examples
include strategies to encodemolecules involved in costimulation
(Krause et al., 1998), the prevention of apoptosis (Charo et al.,
2005), the remodeling of the tumor microenvironment (Kerkar
et al., 2011), and the induction of homeostatic proliferation
(Cheng et al., 2002), as well as CARs encoding chemokine re-
ceptors that promote T cell homing (Moon et al., 2011).
Beyond Boutique: Producing Weapons of Mass
Destruction for the Masses
The potential to target cancer by adoptive transfer of various
lymphocyte subsets is currently being tested in numerous clin-
ical trials. Given that the optimal cell culture conditions are not
the same for distinct lymphocyte subpopulations, there are mul-
tiple approaches that are being tested for ex vivo expansion
(Figure 2). For example, investigators are testing infusion of engi-
neered CD4+ cells, CD8+ cells, Treg cells, invariant NKT cells,
and gamma delta T cells. The use of engineered memory stem
cells (that is, T cells programmed for the most extensive self-
renewal) has significant but as-yet-not-explored potential (Gatti-
noni et al., 2011).
Autologous engineered cell therapies are a paradigm shift
from conventional biologics such as pills, vaccines, small mole-
cule inhibitor molecules, and antibodies in that the approach
requires a patient-specific product. Some have dismissed adop-
tive T cell immunotherapy as a fringe or boutique therapy that
would be impossible to commercialize (Baker, 2011). Indeed,
several challengesmust be overcome before this disruptive ther-
apy can become broadly applicable and widely available. The
barriers that we currently perceive fall into two areas. First, the
cell culture systems must be robust and reproducible. The
T cell engineering process that we and others have developed
requires complex logistics. Some of the variables that need to
be standardized in order to scale this out for widespread use
include developing a leukapheresis network, standardizing and
scaling up the manufacturing of lentiviral vectors, and devel-
oping validated cell-shipping and chain-of-custody procedures.
For example, the cell culture media that will be used for commer-
cial scale must be serum free because there is an insufficient
supply of bovine or human-derived serum to support large-scale
manufacturing (Brindley et al., 2012). Second, personalized cell
therapies cannot become widely available if the cell culture
process requires extensive manipulation by highly skilled scien-
tists and technicians (Mason and Manzotti, 2010). Therefore,
automated culture systems need to be developed. There is pre-
cedent in the automotive industry, where cars were initially man-
ufactured in assembly lines, but manually. Today’s automobiles
are assembled largely by robots and other forms of automation
(Michalos et al., 2010). As engineered T cell processing becomes
more automated, cell products will be produced for greater num-
ber of patients more efficiently. Given the recent entry of the
Immunity
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resources and expertise of the pharmaceutical industry will
create the infrastructure required for the widespread availability
of this disruptive technology. Further clinical development of en-
gineered T cell therapies in large numbers of patients will be
challenging but is justified given the magnitude of therapeutic ef-
fects recently observed.
Lessons from Clinical Trials
Poor in vivo persistence has been a repeating theme in most
T cell adoptive transfer trials where lack of overall efficacy was
observed. Low persistence of infused T cells may be influenced
by a number of variables, including ex vivo culture conditions,
lack of long-term transgene expression, poor effector function-
ality, exhaustion and replicative senescence, and the develop-
ment of anti-infused cell humoral and/or cellular immune
responses. Data generated from both preclinical models and
clinical trials have highlighted a few critical considerations likely
to be important for the ultimately effective clinical development
of T cell therapy.
Animal studies have clearly shown that some T cell subtypes
show desirable qualities in vivo such as enhanced engraftment,
antitumor effect, or survival. A controversy exists as to whether
one subset is preferable; there are reports favoring naive
T cells (Hinrichs et al., 2009), central memory T cells (Berger
et al., 2008), Th17 cells (Muranski et al., 2008), and so-called
memory stem cells (Gattinoni et al., 2011). Despite these preclin-
ical observations, there are as yet no direct clinical comparisons
of the infusions of T cell subsets alone or as a bulk population. A
related controversy is that although it is tempting to try to select a
particular subtype (e.g., CD8+ cytotoxic lymphocytes) for adop-
tive cellular therapy, there is a risk inherent to applying a reduc-
tionist approach to the immune system. For example, there is
compelling evidence that CD4+ T cells are required for CD8+
memory formation, clearly an important quality in the control of
tumor (Sun and Bevan, 2003; Sun et al., 2004). Cell selection
schemata and culture conditions can be optimized to promote
the expansion of T central memory cells (Wang et al., 2012).
It is now well recognized that stimulation of T cells via their
TCR without a second costimulatory signal induces tolerance
and therefore more recent CAR-based technologies have
focused on overcoming this limitation. Thus, although first-gen-
eration CARs depended on intracellular transduction of the
recognition signal via the CD3z chain alone, second- and third-
generation CAR constructs have incorporated second, typically
costimulatory, signaling domains such as those derived from
CD28, ICOS, CD134, or CD137 (Sadelain et al., 2013).
Recent reports from clinical trials that used CAR T cells with
CD137 and TCR zeta signaling domains, which documented
long-term functional persistence of T cells engineered to target
CD19, along with long-lasting clinical remissions and ongoing
B cell aplasia, have highlighted the potential for adoptive T cell
transfer to effect profound long-term functional antitumor activity
(Grupp et al., 2013; Kalos et al., 2011). Most previous clinical tri-
als utilizing engineered T cells were characterized by poor
persistence of the infused product, and the generally disap-
pointing clinical results were probably attributed to inherently
poor proliferative capacity or to rejection by the host of the trans-
ferred product (Kershaw et al., 2006; Park et al., 2007).Expression of costimulatory molecules in trans with CARs has
also been recently demonstrated (Topp et al., 2003), opening up
the possibility for newmodular engineering designs. Ongoing ef-
forts by a number of groups have focused on the evaluation of
signaling domains that have the potential to generate qualita-
tively unique T cell populations that have the potential to drive
T cells to differentiate into unique subsets, such as signaling do-
mains from ICOS that drive human T cells to a Th17 cell pheno-
type (Paulos et al., 2010). Additional strategies have involved the
overexpression in T cells of prosurvival signals such as telome-
rase (Rufer et al., 2001), antiapoptotic genes (Eaton et al.,
2002), and the downregulation of proapoptotic molecules such
as Fas (Dotti et al., 2005). Yet another approach to enhance
T cell survival involves the expression of dominant-negative re-
ceptors for inhibitory molecules such as dominant-negative re-
ceptors for TGF-b (Bollard et al., 2002). Recent data indicate
that effector-like CD27-negative CD8 cells mediate potent pro-
tective immunity and lead to long-lived memory (Olson et al.,
2013). It is likely that CAR T cells ‘‘rewire’’ their signaling and
that the cells that persist as memory cells are different from
those in a natural immune response. Because nonphysiologic
approaches that enhance T cell proliferation and survival have
the potential to generate T cells that do not depend on anti-
gen-specific engagement for survival, each of these approaches
needs to be developed in concert with parallel approaches to
track and mitigate safety concerns.
Exogenous cytokine administration has been reported to
enhance persistence of adoptively transferred CTLs (Yee et al.,
2002). The cytokine most studied in this regard is IL-2, which
has long been utilized as a T cell growth factor and considered
to be essential in adoptive therapy protocols that involved trans-
fer of CD8+ T cells. Recent studies show that although IL-2 in-
duces proliferation of effector CD8+ T cells, it may be deleterious
to the persistence of memory T cells. IL-2 has also been reported
to increase the number of Treg cells (Zhang et al., 2005), which
may be a consequence of the high levels of expression of
CD25, the IL-2 receptor a chain by these cells (Ma et al.,
2006). Studies that have tested the coadministration of CD4+ T
and CD8+ CAR T cells have demonstrated that T cell persistence
is not increased by coadministration of exogenous IL-2, presum-
ably reflecting the helper functions of the CD4+ cell subset (Mit-
suyasu et al., 2000). Other common gamma-chain cytokines
such as IL-7 and IL-15 are also important for T cell expansion
and activation and have shown potential as important modula-
tors of T cell proliferation, differentiation, and function in vivo.
IL-15 and IL-7 may select for the persistence of memory CD8+
T cells and decrease the relative number of Treg cells in mice
(Ku et al., 2000) and nonhuman primates (Berger et al., 2009).
IL-15 appears to induce constitutive telomerase activity in
T cells, which may result in enhanced survival of engineered
T cells by virtue of delaying telomere loss (Hsu et al., 2007).
Advances in T cell engineering allow for the codelivery of cyto-
kines or cytokine receptors into T cells, facilitating autocrine pro-
liferative responses (Evans et al., 1999).
A potential limitation, particularly with the targeting of solid tu-
mors, is the effective trafficking of engineered T cells to sites of
disease. Considerable work to unravel mechanisms for T cell
trafficking has revealed soluble factors, receptors, and adhesion
molecules important for mediating T cell trafficking (Nolz et al.,Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 53
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receptors has highlighted the considerable promise of this
approach to enhance antitumor activity (Mitchell et al., 2008;
Moon et al., 2011). Critical and significant challenges remain
with regard to understanding the mechanisms and obstacles
that impact effective T cell infiltration of solid tumors (Fisher
et al., 2006; Harlin et al., 2009). Fever enhances the adherence
of T cells to the tumor microvasculature (Fisher et al., 2011), so
that the induction of hyperthermia may augment efficacy of
adoptive T cell transfer; parenthetically, some of the beneficial
effects reported after IL-2 coadministration with T cells may be
due to pyrogenic effects.
A significant obstacle to overcome is the exhaustion of T cells
in the immune-suppressivemilieuwithin the tumormicroenviron-
ment (Baitsch et al., 2011). A promising avenue of future research
will involve the evaluation of combination therapies that combine
the adoptive transfer of T cells with the increasing arsenal of
immunomodulatory agents that target T cell inhibitory molecules
such as CTLA-4 and PD-1 (Quezada et al., 2010).
Ex vivo manipulation of T cell products to enhance potency
has the potential to make the product more immunogenic after
transfer because such manipulations commonly introduce engi-
neered, i.e., nonphysiologic, sequences into the recipient cells.
Because most CARs are derived from murine anti-human
scFv, there is the potential for development of both humoral
and cellular responses against CAR sequences or epitopes
from the retroviral vector backbone, and these responses corre-
late with rejection and disappearance of the infused cells from
the circulation (Davis et al., 2010; Lamers et al., 2011). Recently,
anaphylaxis was reported in a patient after infusion of CAR-engi-
neered cells that targeted mesothelin through murine-derived
scFv (Maus et al., 2013). Anaphylaxis has also been reported
after the infusion of autologous human cells cultured in bovine
serum albumin (Macy et al., 1989). Although use of serum-free
cell culture techniques has reduced the potential immunoge-
nicity associated with the use of xenobiotic sera, there is still
the potential for non-self translated open reading frames present
in vector sequences leading to rejection of infused cells. This
phenomenon has been demonstrated in a number of cases
(Berger et al., 2006; Jensen et al., 2010).
Host Conditioning and Lymphodepletion
Immunodepletion with chemoradiotherapy is critical to enhance
engraftment and efficacy of adoptively transferred T cells in lym-
phoma and melanoma (Dudley et al., 2002; Laport et al., 2003).
These results are probably due to multiple mechanisms, based
on studies in mice (Klebanoff et al., 2005).
Data from both preclinical studies and clinical trials have led to
the conclusion that host lymphodepletion prior to T cell infusion
is important to enhance the efficacy of adoptively transferred
T cells (Brentjens et al., 2011; Pegram et al., 2012). Lymphode-
pletion is thought to facilitate T cell expansion and persistence
through the creation of homeostatic space for T cell expansion
and the depletion of cytokine sinks in the form of other immune
cells, leading to the induction of a memory phenotype and
enhanced effector functionality (Dudley et al., 2002; Muranski
et al., 2006; Wrzesinski and Restifo, 2005). Host conditioning in
the form of chemo- or radiotherapy is thought to facilitate
T cell engraftment and survival through the production of homeo-54 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.static cytokines such as IL-15 as a consequence of the inflam-
matory reaction (Miller et al., 2005). The timing of lymphodeple-
tion and conditioning relative to T cell infusion, and whether
particular conditioning regimens are superior is also unclear;
particular regimens have been shown to preferentially induce
immunogenic cell death (Machiels et al., 2001; Obeid et al.,
2007). With regard to timing of the infusion, recent data appear
to suggest that T cell infusion early after conditioning is optimal.
In both adult patients and in a pediatric population we find that
infusion on day +2 is superior to infusions at later time points in
terms of functional immune reconstitution after high-dose
chemotherapy and stem cell infusion (Grupp et al., 2012; Rapo-
port et al., 2009).
In terms of the optimal schedule and dose of T cell infusion, in-
formation in the field is divergent. Whether it is preferable for
T cells to be infused in a single dose or in a fractionated schedule
is unclear. Data from animal models suggest that in the absence
of lymphodepletion, multiple infusions are superior to a single
infusion of T cells (Kircher et al., 2003). Data from bone marrow
transplantation studies suggest that a fractionated infusion
schedule is safer (Peggs et al., 2004); fractionation also affords
the potential to mitigate the severity of toxicity in case of infu-
sion-related adverse events. Optimal dosing of T cells, typically
reported as total number of viable cells infused based on actual
body weight or surface area, is complicated by age-related vari-
ability in total lymphocyte numbers and critical but to-date-unre-
solved variability in the replicative potential and functionality of
the infused cells. Notably, the level of T cell engraftment and
persistence may not correlate with the infused dose, and the
temporal kinetics of maximal engraftment are not yet defined.
In our studies of adoptively transferred autologous CAR
T cells, we often find that the number of cells in the host peaks
2 to 3 weeks after infusion of the cells (Kalos et al., 2011). The
identification of populations of T cells with ‘‘stem cell-like’’ prop-
erties and the recent demonstration of a plasticity of T cell sub-
sets point to the future possibility to engineer small numbers of
T cells with the potential for durable antitumor immunity (Gatti-
noni et al., 2011; Stemberger et al., 2007).
Consequences of Engineering around Tolerance: Off-
Target Recognition
An important evolutionary driver for the developing immune sys-
tem is the establishment of a T cell repertoire with the potential to
be appropriately activated by non-self in an MHC-restricted
manner but to not respond inappropriately to self. Accordingly,
the immune system has evolved to sculpt T cell specificity and
potency with exquisite caution, with both central and peripheral
tolerance mechanisms driving the process to prevent targeting
of self-tissues under physiologic conditions. Engineering and
manipulation of T lymphocytes to have redirected and increased
potency has the potential to alter this natural balance and create
T cells with the enhanced potential to be activated by self, an
issue of considerable concern to the field.
The enhanced potential for self-triggering of engineered T cells
can be a consequence of a number of events, such as a lowered
T cell activation threshold as a result of ex vivo activation,
increased sensitivity of affinity-enhanced T cells to be triggered
by low levels of antigen, or through bypassing peripheral immu-
nosuppressive mechanisms by the introduction of costimulatory
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ex vivo expansion. Perhaps most concerning is the development
of secondary degenerate specificities as a result of the affinity
enhancement. Depending on the mechanism, targeting of self-
tissues can be defined as on-target or off-target. On-target
recognition of normal tissues can be operationally defined as
the recognition and destruction of normal tissues that either
express lower (compared to tumor) levels of the target antigen
or express a different antigen that contains the identical epitope
as that recognized by the parental T cells (TCR-based
approaches) or by the parental antibody (CAR-based
approaches). Off-target recognition of normal tissues can be
operationally defined as the recognition and destruction of
normal tissues that express a different epitope from that recog-
nized by the original targeting agent. Whereas on-target recogni-
tion demands maintenance of the specificity of the original TCR
or antibody, off-target recognition covers a spectrum of degen-
eracy in target epitope recognition, from recognition of variant
peptides with a single amino acid difference to non-peptide-
dependent allo-recognition of target tissues.
Animal models have played significant roles in terms of
providing fundamental insights about engineered T cell potency.
However, animal models are fundamentally limiting in terms of
addressing systems biology questions about T cell therapies.
Beyond the limitation of most animal tumor models not faithfully
recapitulating human cancer, for T cell therapy studies in partic-
ular, model systems fall short because they fail to recapitulate
the integrated biology of an intact human immune system. The
issue of off-tumor/on-target and off-tumor/off-target specificity
is practically impossible to address in preclinical studies,
because animal models are generally noninformative for spe-
cies-specific toxicity and furthermore toxicity has the potential
to be patient specific. Comprehensive repositories of normal
human tissue could be used to facilitate the functional screening
of the potential for off-target toxicities by genetically engineered
T cells. The construction of improved humanized mice or use of
large animals such as dogs will probably be instrumental to be
able to effectively deal with this ongoing issue (O’Connor et al.,
2012).
Increased clinical evaluation of adoptive T cell therapy partic-
ularly via engineered lymphocytes has revealed that targeting of
normal tissues is more than a theoretic concern for the field, with
reported examples of both on- and off- target activity. Because
engineering of T cells increasingly incorporates the use of non-
physiologically derived receptors, it is entirely possible that the
potential for off-target recognitionmay prove to be the exception
rather than the rule. Thus, these early data highlight the real need
to develop strategies to mitigate the potential serious adverse
events that can result from adoptive transfer of potent T cells;
such strategies probably will need to involve more comprehen-
sive screening approaches prior to clinical evaluation of new re-
ceptors, aswell as potent approaches to effectively ablate T cells
should nondesired activity be observed. Antibody-based ap-
proaches to block target epitope recognition have been explored
(Lamers et al., 2013).
As described earlier, adoptive transfer of activated bulk CTL
has been associated with development of an autologous
GVHD syndrome with rash and colitis in about 25% of treated
patients (Rapoport et al., 2009). This event probably representsthe effect of activated T cells being sensitized and subsequently
triggered to recognize self-antigen-derived peptides in the
setting of depleted Treg cells.
On-target toxicity has been reported in cases with T cells en-
gineered with a TCR specific for the carcinoembryonic antigen
resulting in severe inflammatory colitis resulting from expression
of target antigen in normal colon (Parkhurst et al., 2011). Simi-
larly, TCRs targeting melanoma differentiation antigens de-
stroyed normal melanocytes in the skin, ears, and eyes (Johnson
et al., 2009) and more recently with CAR T cells targeting car-
boxy-anhydrase-IX (CAIX), where on-target destruction of biliary
duct epithelial tissue was documented (Lamers et al., 2013).
Severe off-target off-tumor toxicities after infusion of T cells
expressing non-physiologically generated TCR have been
recently reported (Morgan et al., 2013). Neurologic toxicity in
four cases including two deaths were observed in a phase I trial
with a MAGE-A3-specific receptor initially generated in HLA-
A*02 transgenic mice, with toxicity resulting from the unex-
pected expression of epitopes derived from other members of
the MAGE cancer testis family in the CNS. Notably, clinical re-
gressions of diseasewere also reported in this study. Severe car-
diac toxicity was observed in two cases after administration of
T cells expressing an affinity-enhanced TCR that was derived
from an HLA-A*01-restricted TCR that was originally specific
for MAGE A3. Off-tumor and off-target recognition of titin was
demonstrated in these cases (Linette et al., 2013). The engi-
neered TCR was shown to react with MAGE A3 and titin,
whereas the parental TCR reacted only with MAGE A3.
An additional to-date-theoretical concern is that engineered
T cells may pair with endogenous TCR chains, generating novel
specificities (Bendle et al., 2010). This has not yet been observed
in clinical trials.
No Pain, No Gain: The Biological Consequences of
Potent Targeting of Large Tumor Masses
There are a number of differences between the responses eli-
cited by therapeutic tumor vaccines and adoptive T cell transfer
therapy. The response to tumor vaccines and checkpoint
blockade often requires several months to become apparent;
in contrast, the response to T cell transfer is most often observed
in days to weeks. One predicted consequence of triggering rapid
and potent antitumor immunity is the development of a general-
ized proinflammatory immune state. The proinflammatory state
can be a consequence of target antigen-driven activation of
infused T cells or a result of secondary immune activation trig-
gered by the primary T cell activation event. A series of recent
clinical reports have described adverse events associated with
adoptive T cell transfer and attributed this to the induction of a
proinflammatory immune state. These events are temporally
overlapping and may in fact influence each other; nonetheless,
they can be distinguished on the basis of hallmark features.
Cytokine release syndrome (CRS) refers to the production of
proinflammatory cytokines as a direct consequence of T cell trig-
gering. Hallmark features of the syndrome include a systemic
cytokine profile similar to that in response to acute infection, hy-
potension, and high-grade cyclical fevers. Recent reports have
documented CRS in adoptive T cell therapy trials as a conse-
quence of on-target T cell activation (Brentjens et al., 2013; Kalos
et al., 2011; Kochenderfer et al., 2012). The cytokine patterns areImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 55
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2011) and occur several days to weeks after infusion of the
T cells. Notably, with one exception (Morgan et al., 2010), cyto-
kine storm, i.e., the immediate release of cytokines after infusion
of T cells, has not occurred.
Tumor lysis syndrome (TLS) refers to a combination of meta-
bolic complications that occurs as a result of the destruction of
large amounts of tumor and the systemic release of potassium,
phosphate, and nucleic acid, which leads to acute renal failure.
Hallmark clinical features include hypotension, cardiac arrhyth-
mias, and changes in serum biochemistry including elevations
in creatinine, uric acid, potassium, and phosphorus. Delayed
TLS has been reported and observed as a result of adoptive
T cell transfer of CAR T cells engineered to target CD19-positive
malignancies; in this case, TLS occurred 3 weeks after infusion
of gene-modified T cells and was coincident with the peak of
in vivo T cell expansion and tumor elimination (Porter et al.,
2011). In a subsequent case, TLS has been observed as late
as 51 days after infusion of CAR T cells.
Macrophage activation syndrome (MAS) and the closely
related syndrome hemophagocytic lymphohistocytosis (HLH) is
a severe and potentially life-threatening condition typically asso-
ciated with systemic onset juvenile autoimmune disorders (Tang
et al., 2008). Hallmark clinical features of the syndrome include
high fevers, pancytopenia, hemophagocytosis in bone marrow
accompanied by dramatically elevated ferritin and C-reactive
protein levels, activation and proliferation of macrophages and
T lymphocytes, and systemic elevations in IFN-g, GM-CSF, sol-
uble CD163, soluble IL-2 receptor, and IL-6. MAS/HLH has been
reported to be associated with administration of blinatumimab, a
bispecific T cell engaging antibody (BiTe) that activates T cells to
CD19-positive targets in vivo, as well as with the adoptive trans-
fer and potent antitumor activity of CAR targeting pre-B cell
acute lymphocytic leukemia (Grupp et al., 2013). In both of these
cases, MAS was reversed by the administration of the anti-IL6
receptor antibody tocilizumab. The mechanism of this syndrome
remains to be defined. A similar disorder occurs in mice after
repeated stimulation through TLR9 (Behrens et al., 2011).
Controversies and Future Directions in the Field
Clinical data generated principally over the past 5 years suggest
that we are at the threshold of a golden era for adoptive T cell
therapy, where advances in basic immunology have informed
the development of a new field of synthetic immunology that
may increase the potency of approaches that target cancer.
Despite the early successes, a number of fundamental questions
still remain to be resolved before widespread implementation of
this approach to treat cancer.
With regard to the infused cell product, issues related to the
quality, quantity, nature of ex vivo manipulation, and mechanism
of genetic modification are essential to address. With regard to
the nature of the infused product, questions about whether the
most effective strategies will utilize bulk expanded cells or
more defined subpopulations of cells such as central and/or
effector memory subsets (Turtle and Riddell, 2011), virus-spe-
cific T cells (Pule et al., 2008), or potentially products derived
from engineered T cell stem cell precursors (Gattinoni et al.,
2011) will be important to resolve. Data from recent trials demon-
strate that potent and persistent antitumor activity can be gener-56 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.ated through the infusion of small numbers of engineered T cells
(Grupp et al., 2013; Kalos et al., 2011), suggesting that quality
rather than quantity of infused product may be an attribute crit-
ical for potent antitumor activity.
With regard to the tumor, essential questions related to the
relevance of tumor burden remain to be addressed. Adoptively
transferred T cells make complex ‘‘decisions,’’ sensing multiple
inputs and responding to tumor with multiple effector functions
including proliferation and functional differentiation. As a result,
there is the theoretical consideration that the most effective
T cell activation may require higher tumor burden and that ther-
apies may paradoxically be less effective or require higher doses
at earlier stages of disease. Corollary issues related to the impact
of tumor-driven immunosuppressive mechanisms, involving
both surface receptors and soluble mediators, will be important
to unravel.
A fundamental and perhaps controversial issue to address in
the field is the need for long-term persistingmemory T cells in pa-
tients. The crux of this issue relates to balancing the need for
defining the nature of sterilizing cures in the context of persisting
memory T cells and tumor dormancy. Relevant to this issue is
that human tumors can remain dormant for at least 16 years
(MacKie et al., 2003). In our ongoing clinical studies with CAR en-
gineered cells that target CD19, patients remain disease free and
in molecular remission with persisting engineered T cells for at
least 2 years after treatment, but also with ongoing B cell aplasia
resulting from targeting of normal CD19-positive B cells, high-
lighting the practical necessity to eventually ablate engineered
cells and enable normal B cell reconstitution.
An opportunity for adoptive T cell therapy will be strategies
to combine with other antitumor therapies. In particular, thera-
peutic vaccination, checkpoint inhibition, agonistic antibodies,
small molecule inhibitors of tumors, and targeting of tumor
stroma and neo-vasculature may augment current adoptive
transfer technology.
Finally, engineered T cells are poised as a disruptive technol-
ogy advance. The complexity of cells and the challenge of con-
trolling T cells after the introduction of synthetically derived
receptors in a therapeutic setting raises new and daunting
scientific, regulatory, economic, and cultural obstacles to the
establishment of engineered T cells as a widespread and viable
pharmaceutical platform. It is encouraging that the US Food and
Drug Administration has been proactive in balancing the benefits
and risks of subjects in cell-therapy clinical trials (Au et al., 2012).ACKNOWLEDGMENTS
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